In a report released today, Derek Archila from Wells Fargo maintained a Buy rating on aTyr Pharma with a price target of $25.00.
Derek Archila has given his Buy rating due to a combination of factors related to aTyr Pharma’s promising drug candidate, efzofitimod. The upcoming Phase 3 trial results for efzofitimod in treating pulmonary sarcoidosis are anticipated to be a significant catalyst for the company’s stock. Archila believes that the market is currently undervaluing the potential success of this drug, with a substantial increase in share value expected if the trial results are positive.
Archila’s confidence is bolstered by several key points: the mechanism of action for efzofitimod has been clarified through recent publications, and previous trial data has reduced the risk associated with the Phase 3 trial. Additionally, the trial is well-designed to detect meaningful changes in steroid dosage, and management’s insights into the trial data have been positive. However, Archila also notes the risk involved, as failure in the Phase 3 trial could significantly impact the company’s valuation due to the lack of other late-stage assets.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.
